Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial. // The Lancet Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S1470204526002974?dgcid=rss_sd_all
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial. The Lancet Oncology. https://www.sciencedirect.com/science/article/pii/S1470204526002974?dgcid=rss_sd_all
“Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial.” The Lancet Oncology.
@article{article101623,
title = {Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial},
journal = {The Lancet Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S1470204526002974?dgcid=rss_sd_all}
}